- •
Metformin is the first-line glucose-lowering drug to control hyperglycemia in type 2 diabetes mellitus (T2DM); an insulin sensitizer, it decreases hepatic gluconeogenesis and increases glucose disposal in skeletal muscles.
- •
Metformin is safe (small risk for hypoglycemia, weight neutral, and some gastrointestinal [GI] adverse events), is inexpensive, reduces microvascular complication risk, and lowers cardiovascular mortality compared with sulfonylurea therapy.
- •
Metformin-induced lactic acidosis is
Endocrinology and Metabolism Clinics of North America
Metformin: From Research to Clinical Practice
Section snippets
Key points
Drug Development
Metformin (dimethylguanidine) has its roots in a plant, Galega officinalis (French lilac, Goat’s rue, or Spanish sainfoin), rich in guanidine. An outline of the events from 1918, when guanidine was shown to lower blood glucose in animals, to its launch as an oral GLD in 1957 and beyond is shown in Table 1.5
The First-Line Oral Glucose-Lowering Drug for Type 2 Diabetes Mellitus
The only approved indication for metformin use is as “an adjunct to diet and exercise to improve glycemic control in adults and children with type 2 diabetes mellitus.”6 The package insert
Delaying or Preventing the Onset of Type 2 Diabetes Mellitus
The personal and societal burden of T2DM is increasing, with an estimated 415 million people affected globally in 2015.91 Another estimated 318 million people globally have impaired glucose tolerance (IGT).91 One way to reduce the health and economic burden of T2DM is to delay the progression of prediabetes to T2DM. Lifestyle, pharmacotherapy, and bariatric surgery intervention strategies have been reported to be effective.92 Metformin delays the development of or prevents new-onset T2DM (
Metformin Use in Type 2 Diabetes Mellitus Patients with Cancer
Several studies and meta-analyses established an association between diabetes and cancer.126 This association can be explained by hyperinsulinemia, hyperglycemia, and chronic inflammation in T2DM patients, with insulin-stimulating growth of cancerous cells and enhancing mitogenesis. Recently, new observations suggest that metformin may possibly play a role in cancer treatment and prevention.127 Proposed mechanisms for metformin’s anticancer effects includes metformin activation of AMP-activated
Summary
In closing, new knowledge uncovered by research, especially during the past 2 decades, has changed the understanding and use of metformin in the management of T2DM. Although metformin’s cellular and molecular mechanisms of action continue to evolve, how it improves glycemic control is better understood. As the recommended first-line oral GLD to control hyperglycemia in T2DM, and its continued use in combination therapy, metformin is now the most prescribed GLD in the United States. Metformin is
References (163)
- et al.
Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm – 2016 Executive Summary
Endocr Pract
(2016) - et al.
Results of the Glucose-Lowering Effect of WelChol Study (GLOWS): A Randomized, Double-Blind, Placebo-Controlled Pilot Study Evaluating the Effect of Colesevelam Hydrochloride on Glycemic Control in subjects with Type 2 Diabetes
Clin Ther
(2007) - et al.
Comparison of different drugs as add-on treatments to metformin in type 2 diabetes: a meta-analysis
Diabetes Res Clin Pract
(2008) - et al.
Efficacy and safety of an extended-release metformin Formulation In type-2 diabetes mellitus treatment: a systematic review
Value Health
(2015) - et al.
Adverse event notifications implicating metformin with lactic acidosis in Australia
J Diabetes Complications
(2015) - et al.
Acute metformin overdose: Examining serum pH, lactate level and metformin concentrations in survivors versus non-survivors: a systematic review of the literature
Ann Emerg Med
(2009) Metformin-associated lactic acidosis: time to let it go?
J Diabetes Complications
(2015)- et al.
Metformin use and mortality in patients with advanced chronic kidney disease: national, retrospective, observational, cohort study
Lancet Diabetes Endocrinol
(2015) - et al.
Assessment of serum creatinine and kidney function among incident metformin users
Can J Diabetes
(2013) - et al.
Metformin treatment may be associated with decreased levels of NT-proBNP in patients with type 2 diabetes
Adv Med Sci
(2013)
Approaches to glycemic treatment
Diabetes Care
Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes
Diabetes Care
Canadian Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada: Pharmacologic Management of type 2 diabetes
Can J Diabetes
Metformin: its botanical background
Pract Diab Int
World wide experience of metformin as an effective glucose-lowering agent: a meta-analysis
Diabetes Metab Rev
Metformin monotherapy for type 2 diabetes mellitus
Cochrane Database Syst Rev
The effect of oral antidiabetic agents on A1c levels – a systematic review and met-analysis
Diabetes Care
Quantifying the effect of metformin treatment and dose on glycemic control
Diabetes Care
Efficacy and safety of canagliflozin among patients with type 2 diabetes mellitus: a systematic review and meta-analysis
Indian J Endocrinol Metab
Bromocryptine: a Sympatholytic, D2-Dopamine agonist for the treatment of Type 2 diabetes
Diabetes Care
Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus
Ann Intern Med
Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations
Ann Intern Med
Doctor, how certain are we that this diabetes medication is best for me?
Ann Intern Med
Effect of intensive blood-glucose control with merformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group
Lancet
Comparative Effectiveness of Sulfonylurea and Metformin Monotherapy on Cardiovascular Events in Type 2 Diabetes Mellitus - A Cohort Study
Ann Intern Med
Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with type 2 diabetes in UK primary care
Diabet Med
Secondary failure of metformin monotherapy in clinical practice
Diabetes Care
Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemiic control, weight gain, and hypoglycemia in type 2 diabetes
JAMA
Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycemia and weight change in patients with type 2 diabetes: a network meta-analysis
Diabetes Obes Metab
Rationale and Design of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)
Diabetes Care
Evolving metformin treatment strategies in type-2 diabetes: from immediate-release metformin monotherapy to extended-release combination therapy
Am J Ther
Efficacy, tolerability, and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes
Diabetes Care
Adherence in patients transferred from immediate release metformin to a sustained released formulation: a population-base study
Diabetes Obes Metab
The primary glucose-lowering effect of metformin resides in the gut, not the circulation: results from short-term pharmacokinetic and 12-week dose-ranging studies
Diabetes Care
Clinical Pharmacokinetics of metformin
Clin Pharmacokinet
Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review
Diabetologia
Role of AMP-activated protein kinase in mechanism of metformin action
J Clin Invest
Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state
J Clin Invest
Biguanides suppress hepatic glucagon signaling by decreasing production of cyclic AMP
Nature
Metformin Suppresses Expression of the Selenoprotein P Gene vis an AMP-activated Kinase (AMPK)/Fox3a Pathway in H4IIEC3 Hepatocytes
J Biol Chem
Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase
Nature
Metformin activates a duodenal AMPK-dependent pathway to lower hepatic glucose production
Nat Med
Effects of metformin on glucagon-like peptide-1 levels in obese patients with and without type 2 diabetes
Diabetes Nutr Metab
Cellular mechanism of action of metformin
Diabetes Care
Cited by (24)
Cellular toxicity of the metabolic inhibitor 2-deoxyglucose and associated resistance mechanisms
2020, Biochemical PharmacologyCitation Excerpt :Alternatively, several studies aimed at reinforcing the ATP-depleting properties of 2-DG, for example with the use of metformin which is probably the most studied drug in combination with 2-DG. Metformin is a compound widely used for type 2 diabetes treatment which lowers hyperglycemia by inhibiting hepatic lipogenesis and gluconeogenesis and promotes insulin sensitivity (reviewed in [150]). At the cellular level, metformin is a mild mitochondrial complex I inhibitor, leading to decreased ATP levels and AMPK activation, although akin to 2-DG, some consequences of metformin are independent of AMPK [151].
Quantitative In Vivo Proteomics of Metformin Response in Liver Reveals AMPK-Dependent and -Independent Signaling Networks
2019, Cell ReportsCitation Excerpt :The functional conservation of a core set of AMPK substrates mediating metabolism and growth (e.g., acetyl-CoA carboxylase, Raptor, ULK1) make it likely that developing methodologies for a more comprehensive decoding of AMPK substrates will lead to fundamental insights into the minimal number of cellular targets required to move a cell from an anabolic pro-growth state to a nutrient-limited catabolic state. Metformin is a mild mitochondrial complex I inhibitor with modest bioavailability, known to lower hepatic lipogenesis and gluconeogenesis and promote insulin sensitivity (He and Wondisford, 2015; Tan et al., 2016). Hepatic LKB1 has been found to be required for metformin in mice on a high fat diet, and AMPK and its regulation of the downstream target ACC was also reported as critical for the ability of metformin to restore insulin sensitivity during high fat diet (Cao et al., 2014; Duca et al., 2015; Fullerton et al., 2013).
Incidence, factors related to presentation, course and mortality of metformin-associated lactic acidosis in the healthcare area of a tertiary hospital
2019, NefrologiaCitation Excerpt :None of the variables was independently associated with mortality in the multivariate logistic regression analysis. Since its description in 1957 by Jean Stern, metformin has become one of the most prescribed drugs in the world.2 Currently, it is estimated that 150 million patients are being treated with metformin worldwide for control of diabetes.1
Evaluation of the effects of ghrelin and metformin on sperm parameters, testosterone hormones, and immunohistochemical and immunofluorescent markers in an experimental diabetes model
2023, Turkish Journal of Veterinary and Animal SciencesHistone deacetylase functions and therapeutic implications for adult skeletal muscle metabolism
2023, Frontiers in Molecular Biosciences
The authors have nothing to disclose.